- BeOne Medicines has completed pCPA negotiations for Tevimbra (tislelizumab) in combination with gemcitabine and cisplatin for first-line treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (NPC).
- The agreement, concluded on September 25, 2026, marks an important step toward potential publicly funded access for eligible Canadian patients with this rare and often advanced-stage cancer.
- The company will now work with provincial governments and other stakeholders toward reimbursement and listing decisions, with no publicly funded first-line immunotherapy option currently available for this patient population.
- The milestone could expand access to an immunotherapy-based first-line treatment for recurrent/metastatic NPC, addressing an area where treatment options have historically been limited.
Takeaways:
Tevimbra’s completed pCPA negotiations strengthen BeOne’s position in Canada’s NPC immunotherapy market and could establish an early publicly funded first-line option. Provincial reimbursement could accelerate adoption and create a competitive advantage for BeOne, while increasing pressure on alternative systemic therapies in recurrent/metastatic NPC.
Source: CA Newswire
